A role of intracellular mono-ADP-ribosylation in cancer biology

FEBS Journal

Volumn 280, Issue 15, 2013, Pages 3551-3562

  Scarpa, Emanuele S ^a   Fabrizio, Gaia ^a   Di Girolamo, Maria ^a  

^a Department of Cellular and Translational Pharmacology   (Italy)

Author keywords

ADP ribosyltransferase; cancer; clostridial toxin like ADP ribosyltransferase (ARTC); diphtheria toxin like ADP ribosyltransferase (ARTD); diphtheria toxin like ADP ribosyltransferase 15 (ARTD15); mono ADP ribosylation; NAD; poly ADP ribose polymerase 16 (PARP16); post translational modification

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ANTINEOPLASTIC AGENT; BMN 763; BRCA2 PROTEIN; CELL PROTEIN; CEP 9722; DIPHTHERIA TOXIN; GAMMA INTERFERON; GPI 21016; INIPARIB; INO 1001; INTERLEUKIN 4; KARYOPHERIN ALPHA; KARYOPHERIN BETA; KARYOPHERIN BETA1; MONO ADP RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 10; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 15; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 8; NIRAPARIB; OLAPARIB; POLY ADP RIBOSYLTRANSFERASE; RUCAPARIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ACETYLATION; ADENOSINE DIPHOSPHATE RIBOSYLATION; CANCER CELL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; DNA DAMAGE; ENZYME INACTIVATION; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; UNFOLDED PROTEIN RESPONSE;

ADP-RIBOSYLTRANSFERASE; CANCER; CLOSTRIDIAL TOXIN-LIKE ADP-RIBOSYLTRANSFERASE (ARTC); DIPHTHERIA TOXIN-LIKE ADP-RIBOSYLTRANSFERASE (ARTD); DIPHTHERIA TOXIN-LIKE ADP-RIBOSYLTRANSFERASE 15 (ARTD15); MONO-ADP-RIBOSYLATION; NAD; POLY-ADP-RIBOSE POLYMERASE 16 (PARP16); POST-TRANSLATIONAL MODIFICATION;

ADENOSINE DIPHOSPHATE RIBOSE; ADP RIBOSE TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84880333963     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12290     Document Type: Review

References (110)

1. Di Girolamo M, Dani N, Stilla A, &, Corda D, (2005) Physiological relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins. FEBS J 272, 4565-4575.
2. Dani N, Barbosa AJ, Del Rio A, &, Di Girolamo M, (2013) ADP-ribosylated proteins as old and new drug targets for anticancer therapy: the example of ARF6. Curr Pharm Des, 19, 624-633.
3. Koch-Nolte F, Kernstock S, Mueller-Dieckmann C, Weiss MS, &, Haag F, (2008) Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases. Front Biosci 13, 6716-6729.
4. Hassa PO, &, Hottiger MO, (2008) The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 13, 3046-3082.
5. Krueger KM, &, Barbieri JT, (1995) The family of bacterial ADP-ribosylating exotoxins. Clin Microbiol Rev 8, 34-47.
6. Deng Q, &, Barbieri JT, (2008) Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol 62, 271-288.
7. Pallen MJ, Lam AC, Loman NJ, &, McBride A, (2001) An abundance of bacterial ADP-ribosyltransferases-implications for the origin of exotoxins and their human homologues. Trends Microbiol 9, 302-307.; discussion 308.
8. Di Girolamo M, &, Corda D, (2009) Mono-ADP-Ribosylation of Heterotrimeric G Proteins. In: Handbook of Cell Signalling, Vol. 2, (, Bradshaw R, &, Dennis E, eds), pp. 613-618. Academic Press, San Diego.
9. Corda D, &, Di Girolamo M, (2003) Functional aspects of protein mono-ADP-ribosylation. EMBO J 22, 1953-1958.
10. Gibson BA, &, Kraus WL, (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13, 411-424.
11. Mangerich A, &, Burkle A, (2012) Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation. Oxid Med Cell Longev 2012, 321653.
12. Curtin NJ, (2012) In: Drug Discovery Today: Disease Models, Vol. 9, pp. e51-e58. Elsevier B.V, Amsterdam.
13. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, Rodriguez MI, Linares JL, de Almodovar MR, &, Oliver FJ, (2009) PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 47, 13-26.
14. Miwa M, &, Masutani M, (2007) PolyADP-ribosylation and cancer. Cancer Sci 98, 1528-1535.
15. Moss J, Stanley SJ, &, Watkins PA, (1980) Isolation and properties of an NAD- and guanidine-dependent ADP-ribosyltransferase from turkey erythrocytes. J Biol Chem 255, 5838-5840.
16. West RE Jr, &, Moss J, (1986) Amino acid specific ADP-ribosylation: specific NAD: arginine mono-ADP-ribosyltransferases associated with turkey erythrocyte nuclei and plasma membranes. Biochemistry 25, 8057-8062.
17. Moss J, &, Stanley SJ, (1981) Amino acid-specific ADP-ribosylation. Identification of an arginine-dependent ADP-ribosyltransferase in rat liver. J Biol Chem 256, 7830-7833.
18. Godeau F, &, Koide SS, (1983) Xenopus mono(adenosine diphosphate ribosyl) transferase: purification, assay, and properties. Princess Takamatsu Symp 13, 111-118.
19. Zolkiewska A, Nightingale MS, &, Moss J, (1992) Molecular characterization of NAD:arginine ADP-ribosyltransferase from rabbit skeletal muscle. Proc Natl Acad Sci USA 89, 11352-11356.
20. Davis T, &, Shall S, (1995) Cloning of a chicken gene homologous to the rabbit mono-ADP-ribosyltransferase gene. Biochem Soc Trans 23, 207S.
21. Haag FA, Kuhlenbaumer G, Koch-Nolte F, Wingender E, &, Thiele HG, (1996) Structure of the gene encoding the rat T cell ecto-ADP-ribosyltransferase RT6. J Immunol 157, 2022-2030.
22. Okazaki IJ, Kim HJ, &, Moss J, (1996) Cloning and characterization of a novel membrane-associated lymphocyte NAD:arginine ADP-ribosyltransferase. J Biol Chem 271, 22052-22057.
23. Shimoyama M, Tsuchiya M, Hara N, Yamada K, &, Osago H, (1997) Molecular cloning and characterization of arginine-specific ADP- ribosyltransferases from chicken bone marrow cells. Adv Exp Med Biol 419, 137-144.
24. Koch-Nolte F, Haag F, Braren R, Kuhl M, Hoovers J, Balasubramanian S, Bazan F, &, Thiele HG, (1997) Two novel human members of an emerging mammalian gene family related to mono-ADP-ribosylating bacterial toxins. Genomics 39, 370-376.
25. Glowacki G, Braren R, Cetkovic-Cvrlje M, Leiter EH, Haag F, &, Koch-Nolte F, (2001) Structure, chromosomal localization, and expression of the gene for mouse ecto-mono(ADP-ribosyl)transferase ART5. Gene 275, 267-277.
26. Haag F, Koch-Nolte F, Kuhl M, Lorenzen S, &, Thiele HG, (1994) Premature stop codons inactivate the RT6 genes of the human and chimpanzee species. J Mol Biol 243, 537-546.
27. Haag F, &, Koch-Nolte F, (1998) Endogenous relatives of ADP-ribosylating bacterial toxins in mice and men: potential regulators of immune cell function. J Biol Regul Homeost Agents 12, 53-62.
28. Wang J, Nemoto E, &, Dennert G, (1996) Regulation of CTL by ecto-nicotinamide adenine dinucleotide (NAD) involves ADP-ribosylation of a p56lck-associated protein. J Immunol 156, 2819-2827.
29. Liu ZX, Yu Y, &, Dennert G, (1999) A cell surface ADP-ribosyltransferase modulates T cell receptor association and signaling. J Biol Chem 274, 17399-17401.
30. Corda D, &, Di Girolamo M, (2002) Mono-ADP-ribosylation: a tool for modulating immune response and cell signaling. Sci STKE 2002, PE53.
31. Koch-Nolte F, (2013) The art of blocking ARTs: Nanobodies as experimental and therapeutic tools to block mammalian and toxin ADP-ribosyltransferases. FEBS J in press.
32. Lin W, Ame JC, Aboul-Ela N, Jacobson EL, &, Jacobson MK, (1997) Isolation and characterization of the cDNA encoding bovine poly(ADP-ribose) glycohydrolase. J Biol Chem 272, 11895-11901.
33. Moss J, Tsai SC, Adamik R, Chen HC, &, Stanley SJ, (1988) Purification and characterization of ADP-ribosylarginine hydrolase from turkey erythrocytes. Biochemistry 27, 5819-5823.
34. Mueller-Dieckmann C, Kernstock S, Lisurek M, von Kries JP, Haag F, Weiss MS, &, Koch-Nolte F, (2006) The structure of human ADP-ribosylhydrolase 3 (ARH3) provides insights into the reversibility of protein ADP-ribosylation. Proc Natl Acad Sci USA 103, 15026-15031.
35. Niere M, Mashimo M, Agledal L, Doelle C, Kasamatsu A, Kato J, Moss J, &, Ziegler M, (2012) ADP-ribosylhydrolase 3 (ARH3), not poly-ADP-ribose glycohydrolase (PARG) isoforms, are responsible for degradation of mitochondrial matrix-associated poly-ADP-Ribose. J Biol Chem 287, 16088-16102.
36. Fauzee NJ, Li Q, Wang YL, &, Pan J, (2012) Silencing poly(ADP-ribose) glycohydrolase (PARG) expression inhibits growth of human colon cancer cells in vitro via PI3K/Akt/NFkappa-B pathway. Pathol Oncol Res 18, 191-199.
37. Fathers C, Drayton RM, Solovieva S, &, Bryant HE, (2012) Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. Cell Cycle 11, 990-997.
38. Finch KE, Knezevic CE, Nottbohm AC, Partlow KC, &, Hergenrother PJ, (2012) Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG). ACS Chem Biol 7, 563-570.
39. Kato J, Zhu J, Liu C, Stylianou M, Hoffmann V, Lizak MJ, Glasgow CG, &, Moss J, (2011) ADP-ribosylarginine hydrolase regulates cell proliferation and tumorigenesis. Cancer Res 71, 5327-5335.
40. Ame JC, Spenlehauer C, &, de Murcia G, (2004) The PARP superfamily. BioEssays 26, 882-893.
41. Hakme A, Wong HK, Dantzer F, &, Schreiber V, (2008) The expanding field of poly(ADP-ribosyl)ation reactions. Protein Modifications: beyond the usual suspects. Review Series. EMBO Rep 9, 1094-1100.
42. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, Pol E, Frostell A, Ekblad T, Oncu D, et al,. (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30, 283-288.
43. Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, &, Edmondson RJ, (2012) Defective homologous recombination in human cancers. Cancer Treat Rev 38, 89-100.
44. Citarelli M, Teotia S, &, Lamb RS, (2010) Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol Biol 10, 308.
45. Boehler C, &, Dantzer F, (2011) PARP-3, a DNA-dependent PARP with emerging roles in double-strand break repair and mitotic progression. Cell Cycle 10, 1023-1024.
46. Monaco L, Kolthur-Seetharam U, Loury R, Murcia JM, de Murcia G, &, Sassone-Corsi P, (2005) Inhibition of Aurora-B kinase activity by poly(ADP-ribosyl)ation in response to DNA damage. Proc Natl Acad Sci USA 102, 14244-14248.
47. Chang P, Coughlin M, &, Mitchison TJ, (2005) Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol 7, 1133-1139.
48. Kanai M, Tong WM, Sugihara E, Wang ZQ, Fukasawa K, &, Miwa M, (2003) Involvement of poly(ADP-ribose) polymerase 1 and poly(ADP-ribosyl)ation in regulation of centrosome function. Mol Cell Biol 23, 2451-2462.
49. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, et al,. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14, 7917-7923.
50. Tentori L, &, Graziani G, (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52, 25-33.
51. Virag L, &, Szabo C, (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54, 375-429.
52. Jagtap P, &, Szabo C, (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4, 421-440.
53. Leung M, Rosen D, Fields S, Cesano A, &, Budman DR, (2011) Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 17, 854-862.
54. Guha M, (2011) PARP inhibitors stumble in breast cancer. Nat Biotechnol 29, 373-374.
55. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, &, Bradley C, et al,. (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364, 205-214.
56. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, &, Kaufmann SH, (2012) Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 18, 1655-1662.
57. Ohno K, Mitsui T, Tanida Y, Matsuura A, Fujitani H, Niimi T, &, Orita M, (2011) Docking study and binding free energy calculation of poly(ADP-ribose) polymerase inhibitors. J Mol Model 17, 383-389.
58. Costantino G, Macchiarulo A, Camaioni E, &, Pellicciari R, (2001) Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. J Med Chem 44, 3786-3794.
59. Bellocchi D, Macchiarulo A, Costantino G, &, Pellicciari R, (2005) Docking studies on PARP-1 inhibitors: insights into the role of a binding pocket water molecule. Bioorg Med Chem 13, 1151-1157.
60. Gandhi VB, Luo Y, Liu X, Shi Y, Klinghofer V, Johnson EF, Park C, Giranda VL, Penning TD, &, Zhu GD, (2010) Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem Lett 20, 1023-1026.
61. Lehtio L, &, Krauss S, (2013) Tankyrases as drug targets. FEBS J in press.
62. Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, &, Luscher B, (2008) Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell 32, 57-69.
63. Yu M, Schreek S, Cerni C, Schamberger C, Lesniewicz K, Poreba E, Vervoorts J, Walsemann G, Grotzinger J, Kremer E, et al,. (2005) PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 24, 1982-1993.
64. Frias C, Garcia-Aranda C, De Juan C, Moran A, Ortega P, Gomez A, Hernando F, Lopez-Asenjo JA, Torres AJ, Benito M, et al,. (2008) Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer 60, 416-425.
65. Tuncel H, Tanaka S, Oka S, Nakai S, Fukutomi R, Okamoto M, Ota T, Kaneko H, Tatsuka M, &, Shimamoto F, (2012) PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development. Int J Oncol 41, 2079-2086.
66. Goenka S, &, Boothby M, (2006) Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. Proc Natl Acad Sci USA 103, 4210-4215.
67. Di Paola S, Micaroni M, Di Tullio G, Buccione R, &, Di Girolamo M, (2012) PARP16/ARTD15 is a novel endoplasmic-reticulum-associated mono-ADP-ribosyltransferase that interacts with, and modifies karyopherin-1. PLoS ONE 7, e37352.
68. Nachury MV, Maresca TJ, Salmon WC, Waterman-Storer CM, Heald R, &, Weis K, (2001) Importin beta is a mitotic target of the small GTPase Ran in spindle assembly. Cell 104, 95-106.
69. Otto H, Reche PA, Bazan F, Dittmar K, Haag F, &, Koch-Nolte F, (2005) In silico characterization of the family of PARP-like poly(ADP-ribosyl) transferases (pARTs). BMC Genomics 6, 139.
70. Pehrson JR, &, Fried VA, (1992) MacroH2A, a core histone containing a large nonhistone region. Science 257, 1398-1400.
71. Costanzi C, &, Pehrson JR, (1998) Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature 393, 599-601.
72. Angelov D, Molla A, Perche PY, Hans F, Cote J, Khochbin S, Bouvet P, &, Dimitrov S, (2003) The histone variant macroH2A interferes with transcription factor binding and SWI/SNF nucleosome remodeling. Mol Cell 11, 1033-1041.
73. Karras GI, Kustatscher G, Buhecha HR, Allen MD, Pugieux C, Sait F, Bycroft M, &, Ladurner AG, (2005) The macro domain is an ADP-ribose binding module. EMBO J 24, 1911-1920.
74. Dani N, Stilla A, Marchegiani A, Tamburro A, Till S, Ladurner AG, Corda D, &, Di Girolamo M, (2009) Combining affinity purification by ADP-ribose-binding macro domains with mass spectrometry to define the mammalian ADP-ribosyl proteome. Proc Natl Acad Sci USA 106, 4243-4248.
75. Ouararhni K, Hadj-Slimane R, Ait-Si-Ali S, Robin P, Mietton F, Harel-Bellan A, Dimitrov S, &, Hamiche A, (2006) The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity. Genes Dev 20, 3324-3336.
76. Nusinow DA, Hernandez-Munoz I, Fazzio TG, Shah GM, Kraus WL, &, Panning B, (2007) Poly(ADP-ribose) polymerase 1 is inhibited by a histone H2A variant, MacroH2A, and contributes to silencing of the inactive X chromosome. J Biol Chem 282, 12851-12859.
77. Aguiar RC, Takeyama K, He C, Kreinbrink K, &, Shipp MA, (2005) B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J Biol Chem 280, 33756-33765.
78. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, &, Shipp MA, (2000) BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood 96, 4328-4334.
79. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, &, Shipp MA, (2006) BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol 26, 5348-5359.
80. Nelms K, Keegan AD, Zamorano J, Ryan JJ, &, Paul WE, (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17, 701-738.
81. Schindler C, &, Strehlow I, (2000) Cytokines and STAT signaling. Adv Pharmacol 47, 113-174.
82. Darnell JE Jr, (1997) STATs and gene regulation. Science 277, 1630-1635.
83. Ramana CV, Gil MP, Schreiber RD, &, Stark GR, (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23, 96-101.
84. Yang J, Aittomaki S, Pesu M, Carter K, Saarinen J, Kalkkinen N, Kieff E, &, Silvennoinen O, (2002) Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J 21, 4950-4958.
85. Goenka S, Cho SH, &, Boothby M, (2007) Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription. J Biol Chem 282, 18732-18739.
86. Mehrotra P, Riley JP, Patel R, Li F, Voss L, &, Goenka S, (2011) PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. J Biol Chem 286, 1767-1776.
87. Cho SH, Goenka S, Henttinen T, Gudapati P, Reinikainen A, Eischen CM, Lahesmaa R, &, Boothby M, (2009) PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 113, 2416-2425.
88. Cho SH, Ahn AK, Bhargava P, Lee CH, Eischen CM, McGuinness O, &, Boothby M, (2011) Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family. Proc Natl Acad Sci USA 108, 15972-15977.
89. Yanagawa T, Funasaka T, Tsutsumi S, Hu H, Watanabe H, &, Raz A, (2007) Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14. Cancer Res 67, 8682-8689.
90. Gorlich D, Prehn S, Laskey RA, &, Hartmann E, (1994) Isolation of a protein that is essential for the first step of nuclear protein import. Cell 79, 767-778.
91. Fried H, &, Kutay U, (2003) Nucleocytoplasmic transport: taking an inventory. Cell Mol Life Sci 60, 1659-1688.
92. Conti E, &, Izaurralde E, (2001) Nucleocytoplasmic transport enters the atomic age. Curr Opin Cell Biol 13, 310-319.
93. Harel A, &, Forbes DJ, (2004) Importin beta: conducting a much larger cellular symphony. Mol Cell 16, 319-330.
94. Cingolani G, Petosa C, Weis K, &, Muller CW, (1999) Structure of importin-beta bound to the IBB domain of importin-alpha. Nature 399, 221-229.
95. Gorlich D, Kostka S, Kraft R, Dingwall C, Laskey RA, Hartmann E, &, Prehn S, (1995) Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr Biol 5, 383-392.
96. Gorlich D, &, Laskey RA, (1995) Roles of importin in nuclear protein import. Cold Spring Harb Symp Quant Biol 60, 695-699.
97. Yashiroda Y, &, Yoshida M, (2003) Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 10, 741-748.
98. Poon IK, &, Jans DA, (2005) Regulation of nuclear transport: central role in development and transformation? Traffic 6, 173-186.
99. Davis JR, Kakar M, &, Lim CS, (2007) Controlling protein compartmentalization to overcome disease. Pharm Res 24, 17-27.
100. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, &, Leaner VD, (2009) The karyopherin proteins, Crm1 and karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124, 1829-1840.
101. Zheng M, Tang L, Huang L, Ding H, Liao WT, Zeng MS, &, Wang HY, (2010) Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 116, 884-891.
102. Yoshitake K, Tanaka S, Mogushi K, Aihara A, Murakata A, Matsumura S, Mitsunori Y, Yasen M, Ban D, Noguchi N, et al,. (2011) Importin-alpha1 as a novel prognostic target for hepatocellular carcinoma. Ann Surg Oncol 18, 2093-2103.
103. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Oritz Romero PL, Robert T, Balacescu O, et al,. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98, 472-482.
104. Sakai M, Sohda M, Miyazaki T, Suzuki S, Sano A, Tanaka N, Inose T, Nakajima M, Kato H, &, Kuwano H, (2010) Significance of karyopherin-α 2 (KPNA2) expression in esophageal squamous cell carcinoma. Anticancer Res 30, 851-856.
105. Karlberg T, Thorsell AG, Kallas A, &, Schuler H, (2012) Crystal structure of human ADP-ribose transferase ARTD15/PARP16 reveals a novel putative regulatory domain. J Biol Chem 287, 24077-24081.
106. Ron D, &, Walter P, (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8, 519-529.
107. Merksamer PI, &, Papa FR, (2010) The UPR and cell fate at a glance. J Cell Sci 123, 1003-1006.
108. Jwa M, &, Chang P, (2012) PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1α-mediated unfolded protein response. Nat Cell Biol 14, 1223-1230.
109. Zhang K, &, Kaufman RJ, (2008) From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455-462.
110. Zhong Y, Wang Y, Yang H, Ballar P, Lee J, Ye Y, Monteiro MJ, &, Fang S, (2011) Importin β interacts with the endoplasmic reticulum-associated degradation machinery and promotes ubiquitination and degradation of mutant α1-antitrypsin. J Biol Chem 286, 33921-33930.